Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Dewangan, Vandna
- Pathophysiology and Management of Diabetes:A Review
Abstract Views :434 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhansabha, Raipur- 493111(C.G.), IN
1 Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhansabha, Raipur- 493111(C.G.), IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 9, No 4 (2017), Pagination: 219-222Abstract
Diabetes mellitus is a very common metabolic disorder of endocrine system, every year large Number of people suffered from diabetes. According to recent survey in India about 50.8 million people are suffered from diabetes in 2010, and it will rise to 87.0 million till 2030. For the management and prevention of type 1 and type 2 diabetes different approaches have been done throughout the time In this article we have briefly discuss about evaluation of anti-diabetic activity by the use of different in vivo methods including animal model and in vitro method with special reference to cell line techniques. Article also reflect the evaluation of various anti diabetics phytoconstituents which is obtain from different plant source their activity, mechanism of action and it also highlight the advancement that has been done in past few year by different scientist their work title in different beta cell line technique and what output come from their effort to understand diabetes and to overcome it.Keywords
Diabetes Mellitus, Pathophysiology, In-Vivo, In-Vitro Method, Treatment.References
- Duso T, Herr A, Suppliet M. The Welfare Impact Of Parallel Imports: A Structural Approach Applied To The German Market For Oral Anti‐Diabetics. Health economics. 2014 Sep 1; 23(9):1036-57.
- Tao Z, Shi A, Zhao J. Epidemiological perspectives of diabetes. Cell biochemistry and biophysics. 2015 Sep 1; 73(1):181-5.
- Kumar PA, Sreedevi V. A Review On Influence Of Antidiabetic Medications On Quality Of Life.
- Munni JF. Impact of Chronic Diseases on Quality of Life (Doctoral dissertation, East West University).
- Risérus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes. Progress in lipid research. 2009 Jan 31; 48(1):4451.
- Archana C. A survey on Identification of Diabetes Mellitus Patients in Rural Area of Kouluru Village, Panyam Mandal, Kurnool district, Andhra Pradesh.
- Dawood MH. Comparison of serum alpha amylase level between type one and type two diabetes mellitus among Sudanese in Khartoum state in 2015 (Doctoral dissertation, Sudan University of Science and Technology).
- Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. bmj. 2016 Aug 9; 354:i3857.
- DeMasi N. Developing a nutrition education website to increase nutrition knowledge and improve dietary behaviors among California State University, Northridge students (Doctoral dissertation, California State University, Northridge).
- Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. Jama. 2007 Dec 12; 298(22):2654-64.
- Belen Sağlam R, TaskayaTemizel T. A framework for automatic information quality ranking of diabetes websites. Informatics for Health and Social Care. 2015 Jan 2; 40(1):45-66.
- Diabetes Control and Complications Trial. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;2005(353):2643-53.
- National Collaborating Centre for Chronic Conditions (Great Britain). Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. Royal College of Physicians.
- Cavanagh PR. Therapeutic footwear for people with diabetes. Diabetes/metabolism research and reviews. 2004 May 1;20(S1).
- Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005 Feb 1;65(3):385-411.
- Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA internal medicine. 2014 May 1;174(5):773-85.
- Roopashree TS, Dang R, Rani RS, Narendra C. Antibacterial activity of antipsoriatic herbs: Cassia tora, Momordica charantia and Calendula officinalis. International Journal of Applied Research in Natural Products. 2008 Sep 15;1(3):20-8.2008
- Ghule BV, Murugananthan G, Nakhat PD, Yeole PG. Immunostimulant effects of Cappariszeyl anica Linn. leaves. Journal of ethnopharmacology. 2006 Nov 24; 108(2):311-5.
- Dean PM, Matthews EK. Electrical activity in pancreatic islet cells. Nature. 1968 Jul 27; 219(5152):389-90.
- Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, Lauris V. Continuous, clonal, insulin-and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proceedings of the National Academy of Sciences. 1980 Jun 1; 77(6):3519-23.
- Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology. 2004 Feb 1; 145(2):667-78.
- Newgard CB. Cellular engineering and gene therapy strategies for insulin replacement in diabetes. Diabetes. 1994 Mar 1; 43(3):341-50
- Incidence of Moxifloxacin serious adverse drug reactions in Pneumococcal infections virus infected patients detected by a Pharmacovigilance program by laboratory signals in a Tertiary hospital in Chhattisgarh (India)
Abstract Views :144 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmacology, Columbia Institute of Pharmacy, Near Vidhansabha, Village Tekari, Raipur, (C.G.) 493111, IN
1 Department of Pharmacology, Columbia Institute of Pharmacy, Near Vidhansabha, Village Tekari, Raipur, (C.G.) 493111, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 14, No 4 (2022), Pagination: 237-245Abstract
The direct reporting of adverse drug reactions by patients is becoming an increasingly important topic for discussion in the hospital of Pharmacovigilance. Voluntary adverse drug reaction (ADR) reporting is fundamental to medical drug safety surveillance; however, substantial under-reporting exists and is the main limitation of the system. At this time, hospital accepts consumer reports. The World Health Organization estimates that in 2005 and as well as 2019-2021 pneumococcal infections were responsible for the death of 1.6 million human worldwide. Pneumonia, the lungs become filled with fluid and inflamed, leading to breathing difficulties. For some people, breathing problems can become severe enough to require treatment at the hospital with oxygen or even a ventilator. The pneumonia that COVID-19 causes tends to take hold in both lungs. Moxifloxacin, a fluoroquinolone antibiotic, is used for the treatment of respiratory tract, pelvic inflammatory disease, skin, and intra-abdominal infections. Its safety profile is considered favorable in most reviews but has been challenged with respect to rare but potentially fatal toxicities. The most common adverse drug reaction (ADR) constipation is nausea, vomiting, fatigue, alopecia, drowsiness, myelosuppression, skin reactions, anorexia, mucositis, diarrhoea and Medicines that have been particularly implicated in adverse drug reaction-related hospital admissions include anti-platelets, anticoagulants, cytotoxics, immunosuppressant’s, diuretics, anti-diabetics and antibiotics.Keywords
Moxifloxacin, pneumonia, adverse drug reactions, antibiotic, Fungi, intra-abdominal infections, acute bacterial sinusitis, Fatigue, serious cutaneous reactions, inflammation, adverse event, difficulty breathing.References
- Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. The Lancet. 2011 Apr 9;377(9773):1264-75. 2. Gereige RS, Laufer PM. Pneumonia. Pediatrics in Review. 2013 Oct;34(10):438-56.
- Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. The American journal of medicine. 1994 Apr 1;96(4):313- 20.
- Prayle A, Atkinson M, Smyth A. Pneumonia in the developed world. Paediatric respiratory reviews. 2011 Mar 1;12(1):60-9.
- Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. The Lancet. 1987 Mar 21;329(8534):671-4.
- Kollef MH. Prevention of ventilator-associated pneumonia. Critical Care Infectious Diseases Textbook. 2001:707-17.
- Copetti R, Cattarossi L. Ultrasound diagnosis of pneumonia in children. La radiologia medica. 2008 Mar;113(2):190-8.
- Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Critical care medicine. 2004 Jun 1;32(6):1396-405.
- Morgan MS. Diagnosis and treatment of Panton–Valentine leukocidin (PVL)-associated staphylococcal pneumonia. International journal of antimicrobial agents. 2007 Oct 1;30(4):289-96.
- Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not?. Critical care. 2020 Dec;24(1):1-3.
- Verghese AB, Berk SL. Bacterial pneumonia in the elderly. Medicine. 1983 Sep 1;62(5):271-85.
- Mulholland EK, Simoes EA, Costales MO, McGrath EJ, Manalac EM, Gove S. Standardized diagnosis of pneumonia in developing countries. The Pediatric infectious disease journal. 1992 Feb 1;11(2):77-81.
- Fujiwara H, Nishimoto N, Hamano Y, Asanuma N, Miki S, Kasayama S, Suemura M. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Modern rheumatology. 2009 Feb;19(1):64-8.
- Torres A, El-Ebiary M, Riquelme R, Ruiz M, Celis R. Community-acquired pneumonia in the elderly. InSeminars in respiratory infections 1999 Jun 1 (Vol. 14, No. 2, pp. 173-183).
- Wilkins TR, Wilkins RL. Clinical and radiographic evidence of pneumonia. Radiologic technology. 2005 Nov 1;77(2):106-10.
- Chen X, Yin YH, Zhang MY, Liu JY, Li R, Qu YQ. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology. International journal of medical sciences. 2020;17(16):2511.
- Convertino I, Tuccori M, Ferraro S, Valdiserra G, Cappello E, Focosi D, Blandizzi C. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Critical Care. 2020 Dec;24(1):1-6.
- Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. Drugs in R&D. 2012 Jun;12(2):71-100.
- Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clinical therapeutics. 2004 Jul 1;26(7):940-50.
- Chen R, Ma W, Yu X, Liu X, Zhu J, Liang H, Wu X, Guo T. Intravenous moxifloxacin in routine hospital treatment of respiratory tract infections in China: results of a multicenter, noninterventional study. International Journal of General Medicine. 2011;4:317.
- Onoh A, Linnebur SA, Fixen DR. Moxifloxacin-induced tinnitus in an older adult. Therapeutic Advances in Drug Safety. 2018 Apr;9(4):219-21.
- Abramova AA, Gavrilova SM. Estimation of ADR'S risk in hospitalized patients with community-acquired pneumonia. In Science Health 2020. Клинические и теоретические аспекты современной медицины 2020 (pp. 37-37).
- Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. Journal of Antimicrobial Chemotherapy. 2003 May 1;51(suppl_1):21-7.
- Hofer-Dueckelmann C. Multiple drugs Various toxicities leading to death in elderly. Reactions. 2011 Dec 10;1381:10.
- Bassis AV. Pneumococcal vaccine First report of cutaneous RosaiDorfman disease. Reactions. 2011 Nov 12;1377:12.
- Ferner RE. Adverse drug reactions. Medicine. 2016 Jul 1;44(7):416-21.
- Härmark L, van Hunsel F, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug safety. 2015 Apr;38(4):337-47.
- Beijer HJ, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science. 2002 Apr;24(2):46-54.
- Stipanowich TJ. ADR and the “Vanishing Trial”: the growth and impact of “Alternative Dispute Resolution”. Journal of Empirical Legal Studies. 2004 Nov;1(3):843-912.
- Roberts S, Palmer M. Dispute processes: ADR and the primary forms of decision-making. Cambridge University Press; 2005 Oct 20.
- Webber S, Wilkinson AR, Lindsell D, Hope PL, Dobson SR, Isaacs D. Neonatal pneumonia. Archives of disease in childhood. 1990 Feb 1;65(2):207-11.
- Ding R, Logemann JA. Pneumonia in stroke patients: a retrospective study. Dysphagia. 2000 Mar;15(2):51-7.
- Stevens RM, Teres D, Skillman JJ, Feingold DS. Pneumonia in an intensive care unit: a 30-month experience. Archives of Internal Medicine. 1974 Jul 1;134(1):106-11.
- Cook DJ, Kollef MH. Risk factors for ICU-acquired pneumonia. Jama. 1998 May 27;279(20):1605-6.
- Venkatesan P, Gladman J, Macfarlane JT, Barer D, Berman P, Kinnear W, Finch RG. A hospital study of community acquired pneumonia in the elderly. Thorax. 1990 Apr 1;45(4):254-8.
- Scott JA, Wonodi C, Moïsi JC, Deloria-Knoll M, DeLuca AN, Karron RA, Bhat N, Murdoch DR, Crawley J, Levine OS, O’Brien KL. The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. Clinical infectious diseases. 2012 Apr 1;54(suppl_2):S109-16.
- Lutfiyya MN, Henley E, Chang LF, Reyburn SW. Diagnosis and treatment of community-acquired pneumonia. American family physician. 2006 Feb 1;73(3):442-50